S&P 500, Nasdaq, Dow futures pause after Trump rejects Iran's response to peace plan

💊 Novo Nordisk shares rise as Ozempic study shows 15% weight loss in older adults

Novo Nordisk picked up new backing for its obesity lineup Monday, as a pooled analysis from the STEP trials found semaglutide produced significant weight loss among adults aged 65 and older, a group where physicians often proceed cautiously due to frailty and complex health conditions.

This finding arrives at a critical moment for Novo as the company looks to expand Wegovy and Ozempic into new markets, while the weight-loss drug industry shifts toward more accessible oral treatments.

GLP-1 drugs, which mimic a gut hormone tied to appetite and blood sugar regulation, have become a major battleground between Novo Nordisk and Eli Lilly. TechStock² reports.


🧠 Intel stock soars on Apple chip deal report — BofA says Wall Street may be moving too fast

Bank of America bumped up its price target for Intel Corp. to $96 from $56, though it maintained its Underperform rating. Analysts see potential in a chipmaking partnership with Apple, but caution that Intel’s stock may already reflect much of that optimism.

The firm estimates that if Intel captures roughly a quarter of Apple’s chip business, annual foundry sales from the deal could reach $10 billion by 2030.

Intel closed Friday at $124.92, rising 14% and reaching a fresh all-time high, according to Investing.com data.

The rally has pushed the stock up nearly 240% for the year, marking a dramatic turnaround for a chipmaker that has spent years trying to regain its position among the leaders in advanced semiconductor manufacturing. TechStock² reports.


🔋 Fluence Energy stock soars after a revenue miss: the AI power bet behind Wall Street’s re-rating

Fluence Energy shares jumped 27.4% on Friday, capping off a two-day rally fueled by news of master supply deals with two major data-center clients and a record-high $5.6 billion backlog.

The stock wrapped up the session at $24.16 on May 8, after touching $26.98 earlier, according to company data.

Investors are showing renewed appetite for companies positioned to supply power to AI data centers, pushing shares higher.

Fluence’s stock rallied despite a quarterly revenue miss against Wall Street forecasts, a sign that investor focus has shifted beyond short-term results toward order growth, margins, and rising grid demand tied to AI infrastructure expansion. TechStock² reports.


🍎 Apple's supply headache forces surprise Intel partnership

Apple and Intel have reportedly reached a preliminary agreement for Intel to manufacture some Apple-designed chips.

The move could reshape relationships across the semiconductor supply chain while helping Apple reduce its growing dependence on Taiwan Semiconductor Manufacturing.

Taiwan Semiconductor shares traded lower in premarket trading on Monday, while Intel shares moved higher following the report. Benzinga reports.


🧬 Ensysce Biosciences CEO presents at clinical pain symposium in Amsterdam, stock surges in pre-market

Ensysce Biosciences, a clinical-stage pharmaceutical company focused on next-generation pain and central nervous system therapeutics designed to reduce abuse and overdose risk, announced that CEO Dr. Lynn Kirkpatrick presented at the first Pain Therapeutics Summit Europe held in Amsterdam on May 7–8, 2026.

The event brought together global experts to discuss the latest developments in analgesic care and emerging therapeutic candidates.

Dr. Kirkpatrick’s presentation, titled “Chemical Control, Clinical Confidence: Rethinking Opioids,” highlighted a new approach to opioid development focused on chemically engineered drugs with built-in safety controls. Access Newswire reports.

Time (ET)/ Report/ Period

10:00 AM - Existing home sales - April

“People who look for easy money invariably pay for the privilege of proving conclusively that it cannot be found on this earth.”

– Jesse Livermore

Sourced in: Reminiscences of a Stock Operator — GoodReads.

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.